Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

WATCHMAN FLX Versus NOAC for Embolic ProtectION in in the Management of Patients With Non-Valvular Atrial Fibrillation

NCT04394546 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT04394546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04394546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
WATCHMAN FLX Versus NOAC for Embolic ProtectION in in the Management of Patients With Non-Valvular Atrial Fibrillation
Lead sponsor
Boston Scientific Corporation
Phase
Not applicable
Overall status
Active, not recruiting
Start date
October 15, 2020
Completion date
December 31, 2027
Enrollment
3,000 (actual)
Sites
141

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, bleeding, stroke